Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5)

Carolyn D. Britten, Alex Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalInvestigational New Drugs
Volume32
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Investigational Drugs
Phosphatidylinositol 3-Kinases
Neoplasms
2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Erratum to : Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5). / Britten, Carolyn D.; Adjei, Alex; Millham, Robert; Houk, Brett E.; Borzillo, Gary; Pierce, Kristen; Wainberg, Zev A.; LoRusso, Patricia M.

In: Investigational New Drugs, Vol. 32, No. 3, 01.01.2014.

Research output: Contribution to journalComment/debate

Britten, Carolyn D. ; Adjei, Alex ; Millham, Robert ; Houk, Brett E. ; Borzillo, Gary ; Pierce, Kristen ; Wainberg, Zev A. ; LoRusso, Patricia M. / Erratum to : Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5). In: Investigational New Drugs. 2014 ; Vol. 32, No. 3.
@article{adaf97145f6a4f4eb361da2da9f73342,
title = "Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5)",
author = "Britten, {Carolyn D.} and Alex Adjei and Robert Millham and Houk, {Brett E.} and Gary Borzillo and Kristen Pierce and Wainberg, {Zev A.} and LoRusso, {Patricia M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10637-014-0069-6",
language = "English (US)",
volume = "32",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Erratum to

T2 - Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5)

AU - Britten, Carolyn D.

AU - Adjei, Alex

AU - Millham, Robert

AU - Houk, Brett E.

AU - Borzillo, Gary

AU - Pierce, Kristen

AU - Wainberg, Zev A.

AU - LoRusso, Patricia M.

PY - 2014/1/1

Y1 - 2014/1/1

UR - http://www.scopus.com/inward/record.url?scp=84904620998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904620998&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0069-6

DO - 10.1007/s10637-014-0069-6

M3 - Comment/debate

AN - SCOPUS:84904620998

VL - 32

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -